SCHEMBL2911933

SCHEMBL2911933

C=C(C)COc1cc(C)c(-c2cccc(C=O)c2C)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.37
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
MAPT P10636 4/20 0.35
NPSR1 Q6W5P4 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
TP53 P04637 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 2/20 0.35
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
LMNA P02545 3/20 0.35
HTT P42858 3/20 0.35
TSHR P16473 1/20 0.35
GPR174 Q9BXC1 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL562599 0.87 PTGDR2 (0.48) HSD17B10KDM4EALOX15LMNAHPGD
SCHEMBL10203752 0.83 PPARA (0.43) MAPTNPSR1SMN1; SMN2MAPK1HSD17B10
SCHEMBL10203729 0.81 FFAR1 (0.35) MEN1KMT2ASMN1; SMN2ALOX15LMNA
SCHEMBL13117707 0.80 FFAR1 (0.47) KAT6AMAPTFFAR1ALDH1A1CD274
SCHEMBL10203743 0.80 FFAR1 (0.39) MEN1KMT2AMAPTNPSR1SMN1; SMN2
SCHEMBL10203746 0.78 ALDH1A1 (0.41) KMT2AMAPTNPSR1KDM4EUSP2
SCHEMBL561861 0.78 FFAR1 (0.42) FFAR1CYP2C9CD274
SCHEMBL10203744 0.78 FFAR1 (0.42) MEN1KMT2ASMN1; SMN2ALOX15HTT
SCHEMBL2914074 0.77 CD274 (0.34) FFAR1CD274
SCHEMBL562548 0.77 FFAR1 (0.36) MAPTUSP2HPGDPTGDR2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 KAT6A 3965/4885MEN1 2943/4885KMT2A 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.